The individual KDIGO and ADA guidelines as well as the KDIGO-ADA consensus report have recommended the use of SGLT2 inhibitors in patients with DKD and cardiovascular disease on top of standard of care to address the residual risk of DKD progression. The gene discussed is SLC5A2; the disease is diabetic kidney disease.